$BHST

Getty Images (NYSE:GETY) plans to file for bankruptcy under a $533M deal. Navitas (NASDAQ:NVTS) reiterated 'outperform' due to Nvidia collaboration. Cipher Digital (NASDAQ:CIFR) fell 11% on $850M convertible notes plan. BioHarvest (NASDAQ:BHST) ready to license Olive Cell. Namibia Critical Metals (TSX-V:NMI) nearing JV approval. Digi Power X (NASDAQ:DGXX) secures $200M debt financing. Renforth Resources (CSE:RFR) reports gold in Parbec deposit.

BioHarvest Sciences (BHST) announced its Olive Cell, a plant-cell ingredient derived from olives, is ready for commercial licensing. The company completed scale-up, manufacturing readiness, and GRAS process for the product. Olive Cell will be offered through its CDMO business, with commercial production possible once a partner is secured. The company sees potential uses in nutraceuticals, functional nutrition, and cosmetics.

BioHarvest Sciences announced its proprietary Olive Cell composition, derived from olive fruit, has reached commercial readiness. The company completed development, manufacturing, and GRAS process for the asset, which showed promising preclinical activity in liver health models. BioHarvest plans to license and commercialize Olive Cell through its CDMO business, marking its second proprietary plant-cell-derived composition after VINIA.

US stocks traded mixed as chipmakers weighed on markets. Cipher Digital (CIFR) fell 11% on $1B convertible notes plan. BioHarvest (BHST) ready for commercial licensing. Enerflex (EFX) rose 13% on $1B+ contract. Getty Images (GETY) seeks Chapter 11 under $533M restructuring. Domino’s (DPZ) beat EPS estimates but US same-store sales grew just 0.3%. Bumble (BMBL) agreed to $1.3B takeover. J&J (JNJ) raised 2026 forecasts. Citigroup (C) and Wells Fargo (WFC) reported better-than-expected earnings.

BioHarvest Sciences (BHST) announced its Botanical Synthesis platform can produce a next-gen sweetener in a joint program with Tate & Lyle. The collaboration, expanded in May 2026, aims to develop sweeteners with reduced sugar and calories. Both companies reported progress as expected. BioHarvest's platform offers plant-derived ingredients without traditional agriculture, potentially improving consistency and supply reliability.

BioHarvest Sciences Inc (BHST) announced a share repurchase program for up to 5% of its outstanding shares, or 1,133,392 shares. The board believes the market price may not reflect the company's value and growth prospects. CEO Zaki Rakib highlighted the company's evolution and potential revenue streams.

BioHarvest Sciences Inc. (NASDAQ:BHST) launched single-dose VINIA Daily Chews, a new format for its red-grape cell composition. Each chew contains 400 mg of VINIA and 6 mg of piceid resveratrol, clinically shown to improve blood flow. The company aims to expand VINIA's market reach and demonstrate the potential of its Botanical Synthesis platform. The global gummy and chewable supplements market is projected to grow at 14.4% CAGR through 2030, according to Markets and Minds.

Tiziana Life Sciences (TLSA) received a Buy rating and $7 price target from BTIG. Ocean Power Technologies (OPTT) is using Palantir Foundry to improve operations. Sintana Energy (SEI) reported TotalEnergies' acquisition of a 40% interest in Namibia’s PEL 83. American Resources (AREC) joined the Critical Minerals Institute. Thistle Resources (TRCG) launched a Phase 3 drill program. BioHarvest Sciences (BHST) plans to dual-list on the Tel Aviv Stock Exchange. Alvopetro Energy (ALV) reported August

BioHarvest Sciences (NASDAQ: BHST) plans to list its shares on the Tel Aviv Stock Exchange (TASE) by September 8, 2026, alongside its Nasdaq listing. The company, which develops plant-based molecules, aims to provide Israeli investors with access to its shares. BioHarvest filed to register 22.67 million outstanding shares and up to 5.13 million additional shares. CEO Zaki Rakib stated this move supports the company's growth and global ambitions.

BioHarvest Sciences (BHST) reported Q2 2026 revenue of $8.8 million, up 3.8% year over year, with gross profit of $5.1 million and a net loss of $3.7 million ($0.17/share). Cash rose to $16.2 million. The company revised 2026 revenue guidance to $37 million to $40 million and expects consolidated EBITDA losses of $3 million to $5 million, citing a shift toward CDMO growth and a rare fragrance supply agreement.